Over the past decade, a number of studies on iTregs and their relationship to the regulation of immunity and the outcomes of autoimmune diseases have shown that adoptive transfer of Foxp3+ iTregs ameliorates autoimmune disease in mouse models of lupus, gastritis, diabetes, and RA [4, 26–28], although the capacity to apply this therapy in the clinic remains controversial [29, 30]. This evidence concerns the gene FOXP3 and diabetes mellitus.